Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Pharmaceutical Design
  4. Fast Track Articles
  5. Fast Track Article
image of Efficacy of Roxadustat in Anemia with Chronic Kidney Disease

Abstract

Introduction

Anemia is one of the complications of chronic kidney disease (CKD), and its incidence gradually increases as the disease progresses. A major cause of such anemia is the severe erythropoietin deficiency in CKD. Therefore, improvement in red blood cell production is a choice of treatment. Erythropoiesis-stimulating agents (ESAs) have been used for the therapy of anemia induced in CKD. Roxadustat is a novel drug for improving such anemia. This study aimed to compare the efficacy of roxadustat and ESAs in patients with CKD.

Material and Methods

A retrospective analysis of CKD patients with anemia who regularly use roxadustat and ESAs in the Nephrology Department of the Second Affiliated Hospital of Shantou University School of Medicine was carried out. Baseline clinical data and clinical indicators during the medication period were collected and analyzed in both groups.

Results

In this retrospective study, we found that roxadustat was effective in improving anemia. The anemia rate, Hb<11g/dL, before treatment in patients with CKD was 94.55%. The standard rate of patients with CKD anemia was 25.45% after one month of treatment, 54.54% after three months of treatment, and 65.45% after six months of treatment. In the clinical observations of the medication, roxadustat did not differ from ESAs in the treatment of anemia in CKD. However, roxadustat did not improve micro-inflammatory status or increase serum potassium.

Conclusion

Roxadustat did not differ from ESAs in the treatment of anemia in CKD patients. However, it has the potential to lower blood lipids and improve iron deficiency.

Clinical Trial Registration Number

ChiCTR2300071087.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpd/10.2174/0113816128354065250114154721
2025-02-04
2025-03-30

  • From This Site

    /content/journals/cpd/10.2174/0113816128354065250114154721
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Bikbov B. Purcell C.A. Levey A.S. Smith M. Abdoli A. Abebe M. Adebayo O.M. Afarideh M. Agarwal S.K. Agudelo-Botero M. Ahmadian E. Al-Aly Z. Alipour V. Almasi-Hashiani A. Al-Raddadi R.M. Alvis-Guzman N. Amini S. Andrei T. Andrei C.L. Andualem Z. Anjomshoa M. Arabloo J. Ashagre A.F. Asmelash D. Ataro Z. Atout M.M.W. Ayanore M.A. Badawi A. Bakhtiari A. Ballew S.H. Balouchi A. Banach M. Barquera S. Basu S. Bayih M.T. Bedi N. Bello A.K. Bensenor I.M. Bijani A. Boloor A. Borzì A.M. Cámera L.A. Carrero J.J. Carvalho F. Castro F. Catalá-López F. Chang A.R. Chin K.L. Chung S-C. Cirillo M. Cousin E. Dandona L. Dandona R. Daryani A. Das Gupta R. Demeke F.M. Demoz G.T. Desta D.M. Do H.P. Duncan B.B. Eftekhari A. Esteghamati A. Fatima S.S. Fernandes J.C. Fernandes E. Fischer F. Freitas M. Gad M.M. Gebremeskel G.G. Gebresillassie B.M. Geta B. Ghafourifard M. Ghajar A. Ghith N. Gill P.S. Ginawi I.A. Gupta R. Hafezi-Nejad N. Haj-Mirzaian A. Haj-Mirzaian A. Hariyani N. Hasan M. Hasankhani M. Hasanzadeh A. Hassen H.Y. Hay S.I. Heidari B. Herteliu C. Hoang C.L. Hosseini M. Hostiuc M. Irvani S.S.N. Islam S.M.S. Jafari Balalami N. James S.L. Jassal S.K. Jha V. Jonas J.B. Joukar F. Jozwiak J.J. Kabir A. Kahsay A. Kasaeian A. Kassa T.D. Kassaye H.G. Khader Y.S. Khalilov R. Khan E.A. Khan M.S. Khang Y-H. Kisa A. Kovesdy C.P. Kuate Defo B. Kumar G.A. Larsson A.O. Lim L-L. Lopez A.D. Lotufo P.A. Majeed A. Malekzadeh R. März W. Masaka A. Meheretu H.A.A. Miazgowski T. Mirica A. Mirrakhimov E.M. Mithra P. Moazen B. Mohammad D.K. Mohammadpourhodki R. Mohammed S. Mokdad A.H. Morales L. Moreno Velasquez I. Mousavi S.M. Mukhopadhyay S. Nachega J.B. Nadkarni G.N. Nansseu J.R. Natarajan G. Nazari J. Neal B. Negoi R.I. Nguyen C.T. Nikbakhsh R. Noubiap J.J. Nowak C. Olagunju A.T. Ortiz A. Owolabi M.O. Palladino R. Pathak M. Poustchi H. Prakash S. Prasad N. Rafiei A. Raju S.B. Ramezanzadeh K. Rawaf S. Rawaf D.L. Rawal L. Reiner R.C. Jr Rezapour A. Ribeiro D.C. Roever L. Rothenbacher D. Rwegerera G.M. Saadatagah S. Safari S. Sahle B.W. Salem H. Sanabria J. Santos I.S. Sarveazad A. Sawhney M. Schaeffner E. Schmidt M.I. Schutte A.E. Sepanlou S.G. Shaikh M.A. Sharafi Z. Sharif M. Sharifi A. Silva D.A.S. Singh J.A. Singh N.P. Sisay M.M.M. Soheili A. Sutradhar I. Teklehaimanot B.F. Tesfay B. Teshome G.F. Thakur J.S. Tonelli M. Tran K.B. Tran B.X. Tran Ngoc C. Ullah I. Valdez P.R. Varughese S. Vos T. Vu L.G. Waheed Y. Werdecker A. Wolde H.F. Wondmieneh A.B. Wulf Hanson S. Yamada T. Yeshaw Y. Yonemoto N. Yusefzadeh H. Zaidi Z. Zaki L. Zaman S.B. Zamora N. Zarghi A. Zewdie K.A. Ärnlöv J. Coresh J. Perico N. Remuzzi G. Murray C.J.L. Vos T. Global, regional, and national burden of chronic kidney disease, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet 2020 395 10225 709 733 10.1016/S0140‑6736(20)30045‑3 32061315
    [Google Scholar]
  2. Levin A. Djurdjev O. Barrett B. Burgess E. Carlisle E. Ethier J. Jindal K. Mendelssohn D. Tobe S. Singer J. Thompson C. Cardiovascular disease in patients with chronic kidney disease: Getting to the heart of the matter. Am. J. Kidney Dis. 2001 38 6 1398 1407 10.1053/ajkd.2001.29275 11728982
    [Google Scholar]
  3. Dhillon S. Roxadustat: First global approval. Drugs 2019 79 5 563 572 10.1007/s40265‑019‑01077‑1 30805897
    [Google Scholar]
  4. Tang P. Wang H. Regulation of erythropoiesis: Emerging concepts and therapeutic implications. Hematology 2023 28 1 2250645 10.1080/16078454.2023.2250645 37639548
    [Google Scholar]
  5. Barratt J. Sulowicz W. Schömig M. Esposito C. Reusch M. Young J. Csiky B. Efficacy and cardiovascular safety of roxadustat in dialysis-dependent chronic kidney disease: Pooled analysis of four phase 3 studies. Adv. Ther. 2021 38 10 5345 5360 10.1007/s12325‑021‑01903‑7 34523074
    [Google Scholar]
  6. Provenzano R. Szczech L. Leong R. Saikali K.G. Zhong M. Lee T.T. Little D.J. Houser M.T. Frison L. Houghton J. Neff T.B. Efficacy and cardiovascular safety of roxadustat for treatment of anemia in patients with non–dialysis-dependent CKD. Clin. J. Am. Soc. Nephrol. 2021 16 8 1190 1200 10.2215/CJN.16191020 34362786
    [Google Scholar]
  7. Chen N. Hao C. Peng X. Lin H. Yin A. Hao L. Tao Y. Liang X. Liu Z. Xing C. Chen J. Luo L. Zuo L. Liao Y. Liu B.C. Leong R. Wang C. Liu C. Neff T. Szczech L. Yu K.H.P. Roxadustat for anemia in patients with kidney disease not receiving dialysis. N. Engl. J. Med. 2019 381 11 1001 1010 10.1056/NEJMoa1813599 31340089
    [Google Scholar]
  8. Chen N. Hao C. Liu B.C. Lin H. Wang C. Xing C. Liang X. Jiang G. Liu Z. Li X. Zuo L. Luo L. Wang J. Zhao M. Liu Z. Cai G.Y. Hao L. Leong R. Wang C. Liu C. Neff T. Szczech L. Yu K.H.P. Roxadustat treatment for anemia in patients undergoing long-term dialysis. N. Engl. J. Med. 2019 381 11 1011 1022 10.1056/NEJMoa1901713 31340116
    [Google Scholar]
  9. Besarab A. Chernyavskaya E. Motylev I. Shutov E. Kumbar L.M. Gurevich K. Chan D.T.M. Leong R. Poole L. Zhong M. Saikali K.G. Franco M. Hemmerich S. Yu K.H.P. Neff T.B. Roxadustat (FG-4592). J. Am. Soc. Nephrol. 2016 27 4 1225 1233 10.1681/ASN.2015030241 26494833
    [Google Scholar]
  10. Turkmen K. Erdur F.M. Ozcicek F. Ozcicek A. Akbas E.M. Ozbicer A. Demirtas L. Turk S. Tonbul H.Z. Platelet-to-lymphocyte ratio better predicts inflammation than neutrophil-to-lymphocyte ratio in end-stage renal disease patients. Hemodial Int. 2013 17 3 391 396 10.1111/hdi.12040 23522328
    [Google Scholar]
  11. Ahbap E. Sakaci T. Kara E. Sahutoglu T. Koc Y. Basturk T. Sevinc M. Akgol C. Kayalar A.O. Ucar Z.A. Bayraktar F. Unsal A. Neutrophil-to-lymphocyte ratio and platelet-tolymphocyte ratio in evaluation of inflammation in end-stage renal disease. Clin. Nephrol. 2016 85 (2016) 4 199 208 10.5414/CN108584 26521887
    [Google Scholar]
  12. Li P. Xia C. Liu P. Peng Z. Huang H. Wu J. He Z. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in evaluation of inflammation in non-dialysis patients with end-stage renal disease (ESRD). BMC Nephrol. 2020 21 1 511 10.1186/s12882‑020‑02174‑0 33238906
    [Google Scholar]
/content/journals/cpd/10.2174/0113816128354065250114154721
Loading
Efficacy of Roxadustat in Anemia with Chronic Kidney Disease
Bentham Science Publishers ; https://doi.org/10.2174/0113816128354065250114154721
/content/journals/cpd/10.2174/0113816128354065250114154721
/content/journals/cpd/10.2174/0113816128354065250114154721
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: erythropoietin ; renal anemia ; Chronic kidney disease (CKD) ; roxadustat

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test